Skip to main content
. 2022 Mar 17;3(5):100311. doi: 10.1016/j.jtocrr.2022.100311

Table 2.

Tumor Responses

Variables Pem-Based CTx Lorlatinib p Value
All patients, n 22 16
Best overall response, n (%)
 CR 0 0
 PR 10 (45) 7 (44)
 SD 8 (36) 3 (19)
 PD 4 (18) 4 (25)
 NE 0 2 (13)
Clinical benefit, %
 ORR 45 44 0.9169
 DCR 82 63 0.1818

CR, complete response; CTx, chemotherapy; DCR, disease control rate; NE; not evaluable; ORR, objective response rate; PD, progression disease; Pem, pemetrexed; PR, partial response; SD, stable disease.